162 related articles for article (PubMed ID: 28066957)
1. Overexpression of ribonucleotide reductase subunit M1 protein predicts shorter survival in metastatic bladder cancer patients treated with gemcitabine-containing combination chemotherapy.
Matsumura N; Nakamura Y; Kohjimoto Y; Nishizawa S; Kikkawa K; Iba A; Kodama Y; Hara I
Int J Urol; 2017 Mar; 24(3):230-235. PubMed ID: 28066957
[TBL] [Abstract][Full Text] [Related]
2. Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery.
Frischknecht L; Meerang M; Soltermann A; Stahel R; Moch H; Seifert B; Weder W; Opitz I
J Thorac Cardiovasc Surg; 2015 Jun; 149(6):1539-46.e1. PubMed ID: 25840756
[TBL] [Abstract][Full Text] [Related]
3. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.
Bellmunt J; Paz-Ares L; Cuello M; Cecere FL; Albiol S; Guillem V; Gallardo E; Carles J; Mendez P; de la Cruz JJ; Taron M; Rosell R; Baselga J;
Ann Oncol; 2007 Mar; 18(3):522-8. PubMed ID: 17229776
[TBL] [Abstract][Full Text] [Related]
4. Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.
Fisher SB; Fisher KE; Patel SH; Lim MG; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Farris AB; Maithel SK
Cancer; 2013 Jan; 119(2):454-62. PubMed ID: 22760605
[TBL] [Abstract][Full Text] [Related]
5. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
Rosell R; Danenberg KD; Alberola V; Bepler G; Sanchez JJ; Camps C; Provencio M; Isla D; Taron M; Diz P; Artal A;
Clin Cancer Res; 2004 Feb; 10(4):1318-25. PubMed ID: 14977831
[TBL] [Abstract][Full Text] [Related]
6. Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy.
Kim M; Ku JH; Kwak C; Kim HH; Lee E; Keam B; Kim TM; Heo DS; Lee SH; Moon KC
PLoS One; 2015; 10(7):e0133371. PubMed ID: 26200905
[TBL] [Abstract][Full Text] [Related]
7. The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy.
Matsumura N; Nakamura Y; Kohjimoto Y; Inagaki T; Nanpo Y; Yasuoka H; Ohashi Y; Hara I
BJU Int; 2011 Jul; 108(2 Pt 2):E110-6. PubMed ID: 21166756
[TBL] [Abstract][Full Text] [Related]
8. A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer.
Zhang Q; Zhu X; Zhang L; Sun S; Huang J; Lin Y
Cancer Chemother Pharmacol; 2014 Oct; 74(4):839-46. PubMed ID: 25119181
[TBL] [Abstract][Full Text] [Related]
9. Expression of ERCC1, RRM1 and LRP in non-small cell lung cancers and their influence on chemotherapeutic efficacy of gemcitabine concomitant with nedaplatin.
Qiu ZQ; Zhao K
Asian Pac J Cancer Prev; 2014; 15(17):7303-7. PubMed ID: 25227833
[TBL] [Abstract][Full Text] [Related]
10. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.
Ceppi P; Volante M; Novello S; Rapa I; Danenberg KD; Danenberg PV; Cambieri A; Selvaggi G; Saviozzi S; Calogero R; Papotti M; Scagliotti GV
Ann Oncol; 2006 Dec; 17(12):1818-25. PubMed ID: 16980606
[TBL] [Abstract][Full Text] [Related]
11. [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy].
Shi Y; Chen L; Li J; Lü YL; Jiao SC
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):375-82. PubMed ID: 20868593
[TBL] [Abstract][Full Text] [Related]
12. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
Zhang GB; Chen J; Wang LR; Li J; Li MW; Xu N; Wang Y; Shentu JZ
Cancer Chemother Pharmacol; 2012 May; 69(5):1277-87. PubMed ID: 22302408
[TBL] [Abstract][Full Text] [Related]
13. In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy.
Metro G; Zheng Z; Fabi A; Schell M; Antoniani B; Mottolese M; Monteiro AN; Vici P; Lara Rivera S; Boulware D; Cognetti F; Bepler G
Cancer Invest; 2010 Feb; 28(2):172-80. PubMed ID: 19968494
[TBL] [Abstract][Full Text] [Related]
14. RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy.
Yang Z; Fu B; Zhou L; Xu J; Hao P; Fang Z
BMC Urol; 2019 Jul; 19(1):69. PubMed ID: 31340801
[TBL] [Abstract][Full Text] [Related]
15. [Relations between RRM1 protein expression levels and effects of gemcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer patients].
Gao Z; Han B; Shen J; Gu A; Zhong H
Zhongguo Fei Ai Za Zhi; 2011 Apr; 14(4):340-4. PubMed ID: 21496433
[TBL] [Abstract][Full Text] [Related]
16. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
Surgery; 2013 Apr; 153(4):565-75. PubMed ID: 23253379
[TBL] [Abstract][Full Text] [Related]
17. Setting the stage for tailored chemotherapy in the management of non-small cell lung cancer.
Simon GR; Begum M; Bepler G
Future Oncol; 2008 Feb; 4(1):51-9. PubMed ID: 18241000
[TBL] [Abstract][Full Text] [Related]
18. RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin.
Muñoz-Montaño W; Muñiz-Hernández S; Avilés-Salas A; Catalán R; Lara-Mejía L; Samtani-Bassarmal S; Cardona AF; Mendoza-Desión J; Hernández-Cueto D; Maldonado A; Baay-Guzmán G; Huerta-Yepes S; Arrieta O
BMC Cancer; 2021 Aug; 21(1):892. PubMed ID: 34353292
[TBL] [Abstract][Full Text] [Related]
19. Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy.
Sasaki H; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
Br J Cancer; 2014 Sep; 111(7):1275-84. PubMed ID: 25032731
[TBL] [Abstract][Full Text] [Related]
20. [Relationship between the efficacy of gemcitabine/cisplatin adjuvant chemotherapy and RRM1 protein expression in postoperative NSCLC patients].
Ma K; Li E; Guo Y; Wang X; Sun H; Shao G
Zhonghua Zhong Liu Za Zhi; 2014 Jul; 36(7):505-10. PubMed ID: 25327655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
